Mucosal and systemic administrations of high dose antigens induce long-lasting peripheral T cell tolerance. We and others have shown that high dose peripheral T cell tolerance is mediated by anergy or deletion and is preceded by T cell activation. Co-stimulatory molecules B7-1 (CD80)/B7-2 (CD86) and their counter-receptors CD28/CTLA-4 play pivotal roles in T cell activation and immune regulation. In the present study, we examined the roles of the B7 co-stimulation pathway in the generation of high dose peripheral T cell tolerance. We found that blocking B7:CD28/CTLA-4 interaction at the time of tolerance induction partially prevented T cell tolerance, whereas selective blockade of B7:CTLA-4 interaction completely abrogated peripheral T cell tolerance induced by either oral or i.p. antigens. These results suggest that CTLA-4-mediated feedback regulation plays a crucial role in the induction of high dose peripheral T cell tolerance.
Introduction
The co-stimulatory molecules B7-1 and B7-2 can both upand down-regulate the functions of T cells. Interaction of B7 with CD28 delivers positive signals that are required for T cell activation (1) (2) (3) (4) (5) , whereas interaction of B7 with CTLA-4 may deliver negative signals that are crucial for immune downregulation (6) (7) (8) . The importance of CTLA-4 in immune regulation was underscored by the observation that germline disruption of the CTLA-4 gene induced systemic lymphoproliferative disorders in mice and early death of the animals (9, 10) . However, the exact roles of CTLA-4 in the development of central and peripheral immune tolerance are unknown.
Oral tolerance is a classic form of antigen-driven peripheral T cell tolerance (11) (12) (13) . In addition to preventing systemic immune responses to food antigens, oral tolerance is also being employed to suppress autoimmune diseases in animals and in humans (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . Depending on the dose of antigen administered, oral tolerance may be mediated by deviation, anergy or deletion. Low doses of antigen preferentially tolerize T h 1 cells, and activate T h 2 and transforming growth factor-β-secreting cells (25) (26) (27) (28) , whereas high doses of antigen anergize or delete both T h 1 and T h 2 cells (18, 29, 30) . Similarly, peripheral T cell tolerance can also be induced by nasal, i.v. or i.p. administration of high dose antigens; and clonal Correspondence to: Y. Chen Transmitting editor: J. A. Bluestone Received 17 July 1997, accepted 5 January 1998 deletion, clonal anergy as well as immune deviation have been implicated in mediating T cell hyporesponsiveness (31) (32) (33) (34) (35) . The mechanisms of induction of peripheral T cell tolerance by high dose antigens are not well understood. We and others have shown that T cell activation precedes the development of T cell tolerance (30, 36) . In this report, we investigated the role of CD28 and CTLA-4 in the induction of high dose peripheral T cell tolerance. We found that blocking both CD28 and CTLA-4 signals partially prevented T cell tolerance, whereas selective blockade of CTLA-4 completely abrogated T cell tolerance induced by high dose antigens. These results suggest that CTLA-4-mediated feedback regulation is directly involved in the induction of high dose peripheral T cell tolerance.
Methods

Mice
Female BALB/c mice, 6-8 weeks of age, were purchased from Jackson Laboratory (Bar Harbor, ME 
Statistical analysis
Statistical significance of differences between groups was determined by ANOVA.
Results
B7
blockade partially reversed T cell tolerance induced by high dose oral antigen.
To examine the roles of co-stimulatory molecules in the induction of high dose oral tolerance, we first blocked B7:CD28/CTLA-4 interaction at the time of antigen feeding Blood was collected via retro-orbital vein plexus either before the first injection (day -3 or -4), or 1, 5 or 10 days after the last injection. Serum levels of CTLA-4-Ig and anti-CTLA-4 mAb were determined by dot-blotting using biotinylated goat anti-human Ig (B) (Jackson ImmunoResearch, West Chester, PA) or mouse anti-hamster Ig (C) (PharMingen, San Diego, CA), followed by avidin-peroxidase and DAB substrate. No CTLA-4-Ig or anti-CTLA-4 mAb were detected in non-treated mice or mice 10 days after the treatment. A total of 5 µl of serum was used per sample. The sensitivity of this assay was 100 pg/ml.
using CTLA-4-Ig fusion protein. Figure 1 illustrates the time schedule used for the current investigation. Mice were first tolerized with high dose OVA (50 mg) once a day for a total of five feedings. At the time of the feeding, mice were also injected i.p. with CTLA-4-Ig or a control Ig. All immunizations were performed a minimum of 10 days after in vivo administration of CTLA-4-Ig.
To ensure that CTLA-4-Ig will not interfere with the in vivo priming of T cells following immunization, we determined the serum levels of CTLA-4-Ig at different time points following i.p. injection of CTLA-4-Ig. As shown in Fig. 1(B) , CTLA-4-Ig was readily detectable in mice 1-5 days after CTLA-4-Ig injection but not 10 days after the injection, suggesting that CTLA-4-Ig may not be present at the time of immunization. Similarly, when mice were treated with anti-CTLA-4 mAb, the antibody was detected in mice 1-5 days after antibody injection but not 10 days after the injection (Fig. 1C ). As will be further discussed below, injection of CTLA-4-Ig or anti-CTLA-4 mAb 10-14 days before immunization had little effect on the subsequent T cell activation as judged by in vitro functional studies. By contrast, injection of CTLA-4-Ig at the time of immunization has been reported to dramatically inhibit T cell priming (40) (41) (42) .
As shown in Fig. 2 , oral administration of OVA induced long-lasting T cell tolerance in mice. The production of IFN-γ, IL-4 as well as the proliferation of OVA-specific T cells in OVA-fed mice were significantly suppressed as compared to PBS-fed mice. Injection of CTLA-4-Ig 23 days before immunization had little effect on the reactivity of OVA-specific T cells in PBS-fed animals (Fig. 2) . Surprisingly, the production of IFN-γ in OVA-fed mice was restored to the control level by i.p. administration of CTLA-4-Ig, suggesting that tolerance induction of IFN-γ responses may require the co-stimulatory molecule B7. By contrast, the inhibition of IL-4 in OVA-fed mice was not affected by CTLA-4-Ig nor the proliferation of OVA-specific T cells in the culture (Fig. 2) . Little IL-2 was detected in these cultures. IL-10 was detected, but no significant differences were noted between control and CTLA-4-Ig treated groups (the maximum levels of IL-10 in control and CTLA-4-Ig treated groups were 133 Ϯ 10 and 136 Ϯ 23 respectively). These results suggest that blocking B7:CD28/ CTLA-4 interaction partially hampered the induction of T cell tolerance. In parallel studies, we also tested higher dose of CTLA-4-Ig (500 µg per mouse) during the induction of oral tolerance-no additional effects on oral tolerance were observed (Samoilova and Chen, unpublished).
CTLA-4 blockade completely abrogates high dose oral tolerance
As CD28 and CTLA-4 may deliver opposing signals to T cells, blocking B7 may block both positive and negative T cell costimulation. To test directly the role of CTLA-4 in oral tolerance, we selectively blocked the CTLA-4 signal using anti-CTLA-4 mAb 4F10 (6, 43) . Mice were injected with anti-CTLA-4 mAb at the time of each feeding and immunized 10 days later. As shown in Fig. 3 , oral administration of high dose OVA induced profound tolerance of both IL-2/IFN-γ-producing T h 1 and IL-4/IL-10-secreting T h 2 cells. Injection of anti-CTLA-4 mAb 10 days before immunization had no significant effect on T cell proliferation or cytokine production in PBS-fed mice. Remarkably, co-administration of anti-CTLA-4 mAb at the time of antigen feeding completely abrogated tolerance of both T h 1 and T h 2 cells. Specifically, the maximum IFN-γ produced by PBS-fed mice was 2144 Ϯ 153 pg/ml which was reduced to 459 Ϯ 80 pg/ml in OVA-fed mice. This was reversed to Mice were immunized with 100 µg of OVA in CFA 20 days after the last feeding and sacrificed 11 days later. Splenocytes, 1ϫ10 6 cells/ well, were cultured in 0.2 ml of serum-free medium (X-vivo 20) with different concentrations of OVA. Culture supernatants were collected 40 h later and cytokine concentrations were determined by ELISA. For proliferation assays, 1 µCi [ 3 H]thymidine was added to each culture 72 h later. Cells were harvested and radioactivity counted 16 h later using a flatbed β-counter. Each data point represents a mean Ϯ SD from four mice (SD smaller that the size of the symbol is not shown). Data are representative of two experiments. For proliferation and IL-4 production, the differences between PBS-fed and OVA-fed groups were statistically significant (P Ͻ 0.01); for IFN-γ production, the differences between PBS-fed and OVA-fed groups were statistically significant (P Ͻ 0.01) only for mice treated with control Ig. Open blocks ϭ PBS, solid blocks ϭ OVA.
3388 Ϯ 66 pg/ml by co-administration of anti-CTLA-4 mAb at the time of OVA feeding. Similarly, the maximum level of IL-4 produced in PBS-fed mice was 104 Ϯ 11 pg/ml which was reduced to 3 Ϯ 1 pg/ml in OVA-fed mice. This reduction was reversed to 79 Ϯ 17 pg/ml in mice injected with anti-CTLA-4 mAb. Similarly, the maximum [ 3 H]thymidine incorporation of splenocytes of PBS-fed mice was 2934 Ϯ 384 c.p.m., which was reduced to 1346 Ϯ 331 in OVA-fed mice. Injection of anti-CTLA-4 mAb 10 days before immunization had little effect on subsequent T cell priming (c.p.m. ϭ 4201 Ϯ 26 in mice fed with PBS and injected with anti-CTLA-4 mAb), but feeding high dose OVA in the presence of these antibodies induced Mice were immunized with 100 µg of OVA in CFA 10 days after the last feeding and sacrificed 11 days later. Splenocytes, 1.5ϫ10 6 cells/ well, were cultured in 0.2 ml serum-free medium containing different amounts of OVA. Culture supernatants were collected 40 h later and cytokine concentrations were determined by ELISA. For proliferation assays, 1 µCi [ 3 H]thymidine was added to each culture 72 h later. Cells were harvested and radioactivity counted 16 h later using a flatbed β-counter. The experiments were repeated twice with similar results. For both IFN-γ and IL-4, the differences between OVA-fed/ control Ig-injected group and all other groups were statistically significant (P Ͻ 0.001). For c.p.m., IL-2 and IL-10, the differences between OVA-fed/control Ig-injected group and all other groups were also statistically significant (P Ͻ 0.01). Open blocks ϭ PBS, solid blocks ϭ OVA.
no tolerance (c.p.m. ϭ 3949 Ϯ 182 in mice fed with OVA and injected with anti-CTLA-4 mAb).
CTLA-4 blockade abrogates high dose tolerance induced by i.p. antigen
To test whether the effect of CTLA-4 blockade on oral tolerance may be generalized to other models of peripheral tolerance, Mice were immunized with 100 µg of OVA in CFA 10 days after the last feeding and sacrificed 11 days later. Splenocytes, 1.5ϫ10 6 cells/well, were cultured in 0.2 ml serum-free medium containing different amounts of OVA. Culture supernatants were collected 40 h later and cytokine concentrations were determined by ELISA. The experiments were repeated twice with similar results. For all the cytokines, the differences between OVAfed/control Ig-injected group and all other groups were statistically significant (P Ͻ 0.01). For IL-4, the differences between control Ig and anti-CTLA-4 mAb injected groups were also statistically significant (P Ͻ 0.05). Open blocks ϭ PBS, solid blocks ϭ OVA.
we tested the effect of CTLA-4 blockade on peripheral tolerance induced by i.p. injection of high dose antigen. As shown in Fig. 4 , i.p. administration of OVA induced marked suppression of OVA-specific T h 1 and T h 2 cells; but injection of anti-CTLA-4 mAb at the time of antigen treatment completely abrogated this effect. Injection of anti-CTLA-4 mAb alone had little effect on the production of IFN-γ and IL-10 in nontolerized animals, although the production of IL-4 was slightly decreased in non-tolerized animals.
In parallel experiments, mice tolerized by i.p. administration of OVA were also treated with CTLA-4-Ig (100 µg/mouse) using a similar strategy as outlined in Fig. 1 . The anti-OVA immune responses in these mice were then compared with those treated with control Ig. Similar to what we observed in the oral tolerance model (Fig. 2) , injection of CTLA-4-Ig had little effect on the production of IL-4 and IL-10 by OVA-specific T cells in tolerized animals; but the production of IFN-γ in these animals was partially reversed by CTLA-4-Ig injection (Samoilova and Chen, unpublished).
Transient CTLA-4 blockade does not induce hyper-activation of T lymphocytes.
The above results strongly suggest that, in the presence of anti-CTLA-4 mAb, peripheral tolerance may not be induced by either oral or i.p. antigens. As permanent deficiency in CTLA-4 function leads to hyper-activation of lymphocytes (9, 10) , it is important to determine whether anti-CTLA-4 mAb induces direct T cell activation. To address this issue, we first tested whether five injections of 200 µg anti-CTLA-4 mAb in normal mice resulted in polyclonal activation of T cells in vivo. Thus, two groups of BALB/c mice were treated either with 200 µg of anti-CTLA-4 mAb or control Ig every day for a total of 5 times and sacrificed 2 days after the last treatment. Lymph nodes, spleen, liver and thymus were then collected. No gross abnormalities were ever observed in any of these organs and no significant increases in the total cell numbers were noted in the spleen and lymph nodes. When the splenocytes were cultured in vitro (at 5ϫ10 6 /ml in X-vivo 20 culture medium), no IL-2 was detected in the supernatant; addition of concanavalin A at a final concentration of 2.5 µg/ml led to the production of 28,990 Ϯ 1302 and 20,175 Ϯ 294 pg/ml of IL-2 by splenocytes of mice treated with control Ig and anti-CTLA-4 mAb respectively.
As the frequencies of antigen-specific T cells in normal mice are extremely low, the effect of anti-CTLA-4 mAb on antigen-specific cells may not be directly assessed in the above experiments. We, therefore, tested the effect of anti-CTLA-4 mAb on OVA-specific T cells in TCR transgenic mice specific for OVA. As shown in Fig. 5 , splenocytes of TCR transgenic mice proliferate and secret IL-2 and IFN-γ upon ex vivo stimulation with OVA. Pre-treatment of mice with anti-CTLA-4 mAb affected neither the proliferation nor cytokine secretion of these cells. Consistent with these results, little or no CTLA-4 was detected by flow cytometry on CD4 ϩ T cells in TCR transgenic mice treated with either control Ig or anti-CTLA-4 mAb, whereas high levels of CTLA-4 expression were detected in mice treated with high dose i.p. OVA (Samoilova and Chen, unpublished). Based on these observations, we concluded that transient blockade of CTLA-4 may not lead to polyclonal activation of T cells in vivo.
Discussions
Results presented above strongly suggest that the co-stimulatory molecule B7 may be directly involved in the induction of high dose peripheral tolerance. It has long been speculated that high dose peripheral T cell tolerance may be induced as a result of TCR signaling (first signal) in the absence of a second signal. Although the nature of the second signal is still under intense investigation, B7-mediated co-stimulation is now being considered to be the most likely candidate. Yet, although resting B cells do not express the co-stimulatory molecule B7, dendritic cells and macrophages constitutively express B7-2 (40, 44) . Thus, although innocuous soluble antigens may not up-regulate B7 expression, they may still be processed by dendritic cells and macrophages in the presence of the default level (not up-regulated level) of B7 costimulation. This may explain the pre-activation phenomenon observed during the inductive phase of oral (30, 36) and i.v. tolerance (34, 45) . Furthermore, transgenic expression of B7 on B cells failed to abrogate high dose peripheral tolerance (46) . Our recent studies suggested that transient expression of B7-1 in systemic lymphoid organs by somatic gene transfer using recombinant adenovirus carrying the B7-1 gene failed to abrogate high dose peripheral tolerance (Samoilova and Chen, unpublished). Thus it appears that high dose tolerance can be induced in the presence of B7 and that the constitutively expressed B7 may play an active role in the generation of high dose tolerance.
Our results also suggest that the roles of B7 in high dose oral and i.p. tolerance may be primarily mediated through CTLA-4. Unlike CD28, CTLA-4 is expressed mainly after T cell activation and has been shown to suppress T cell functions in a number of systems (6, 8, 43) . Germline disruption of CTLA-4 gene led to heightened lymphocytic proliferation and multiorgan inflammatory disorders (9,10). Our observation that high dose tolerance was defective in mice transiently deprived of CTLA-4 function may help explain the abnormalities in CTLA-4-deficient mice. It is possible that peripheral tolerance to self and dietary antigens may not be generated in these animals, which in turn leads to systemic lymphoproliferation. The exact mechanisms whereby high dose antigens activate CTLA-4 feedback regulation in the absence of a detectable immune response are unknown. We and others have shown that T cell pre-activation does occur during tolerance induction (30, 34, 36, 45) . It is plausible that this activation may be sufficient to up-regulate CTLA-4 expression but inadequate to provoke a complete immune response. Alternatively, the presence of high dose antigens in the microenvironment of T cell activation may activate other mechanisms of feedback regulation including propriocidal cell death mediated by FasL or tumor necrosis factors as described by Lenardo and colleagues (47, 48) . Further experiments are needed to elucidate the intrinsic connections among these different feedback regulatory pathways.
Consistent with our observation that B7:CTLA-4 interaction is involved in peripheral T cell tolerance, CTLA-4 has also been reported to play important roles in other tolerance models (49) (50) (51) . Thus, Perez et al. recently showed that B7 blockade with CTLA-4-Ig prevented the induction of T h 1 tolerance induced by i.v. antigen; the effect appeared to be mediated through CTLA-4 as blocking CTLA-4 but not CD28 abrogated T cell tolerance (49) . Similarly, Bluestone and Lane et al. reported that superantigen-induced T cell tolerance in mice can be significantly hampered by systemic administration of anti-CTLA-4 mAb (50) or transgenic expression of CTLA-4-Ig (51) .
Although deficiency in CTLA-4 led to systemic hyperactivation of lymphocytes, transient blockade of CTLA-4 function by specific mAb may not lead to systemic T cell activation. This was probably due to the fact that CTLA-4 is normally not expressed by resting T cells (6, 39) . Thus, in the absence of specific antigens, transient blockade of CTLA-4 function may not alter the function of antigen-specific T cells. The polyclonal activation of T cells in CTLA-4 deficient mice may be a result of a chronic progressive activation of T cells by various environmental pathogens over a relatively long period of time or a result of deficiency in peripheral tolerance to self antigens. Our results also suggest that transient blockade of CTLA-4 function may be a feasible strategy to up-regulate immune responses for treatment of such diseases as cancer and microbial infections. Of note is that our experiments cannot exclude the possibility that anti-CTLA-4 mAb may promote the proliferation of a minor population of low-affinity OVAspecific T cells that may have escaped tolerance induction following antigen feeding. Experiments are under way to address this issue.
In summary, we have discovered a crucial role for CTLA-4 in the induction of peripheral high dose oral tolerance. These findings may have important ramifications for understanding the mechanisms of peripheral T cell tolerance and for designing novel strategies for the treatment of immune-related disorders.
